SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
-------------------------------
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES ACT OF 1934
Date of report (Date of earliest event reported): May 29, 2002
------------
CYTOGEN CORPORATION
-------------------
(Exact Name of Registrant as Specified in Charter)
Delaware 000-14879 222322400
--------------------------------------------------------------------------------
(State or Other Jurisdiction (Commission File Number) (IRS Employer
of Incorporation) Identification No.)
600 College Road East, CN 5308, Princeton, NJ 08540
--------------------------------------------------------------------------------
(Address of Principal Executive Offices) (Zip Code)
(609) 750-8200
------------------------------------------------
(Registrant's telephone number,
including area code)
-------------------------------------------------------------
(Former Name or Former Address, if Changed Since Last Report)
Item 5. Other Events.
On May 29, 2002, Cytogen Corporation (the "Company") issued a press release
reporting the Company's financial guidance and outlining the Company's strategic
planning and operations for 2002. Subsequently, on May 30, 2002, the Company
issued a joint press release with Draximage Inc., the radiopharmaceutical
subsidiary of DRAXIS Health Inc., announcing the launch of DRAXIS Health's
BrachySeed Palladium-103 product in the United States for the treatment of
prostate cancer.
Each such press release is attached hereto as Exhibit 99.1 and Exhibit
99.2, respectively, and each is incorporated herein by reference. The foregoing
description of each such press release is qualified in its entirety by reference
to each such respective document.
Item 7. Financial Statements, Pro Forma Financial Information and
Exhibits.
(c) Exhibits.
Exhibit No. Description
----------- -----------
99.1 Press release of the Company dated May 29, 2002
99.2 Press release of the Company dated May 30, 2002
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
Cytogen Corporation
By: /s/ Lawrence R. Hoffman
------------------------------
Lawrence R. Hoffman,
Chief Financial Officer
Date: May 30, 2002